Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsMasakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
Life of this patent
Estimating the term…
Abstract
A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the β-blocker. For the administration mode, each drug can be administered in combination or in mixture.
Claims12
A therapeutic agent for glaucoma comprising a combination of a Rho kinase inhibitor and a β-blocker.
A therapeutic agent for glaucoma characterized in that it comprises a combination of a Rho kinase inhibitor and a β-blocker, and they complement and/or enhance their actions each other.
A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a β-blocker to a patient.
A method of treating glaucoma characterized by administering effective amounts of a Rho kinase inhibitor in combination with a β-blocker to a patient, thereby they complementing and/or enhancing their actions each other.
Use of a combination of a Rho kinase inhibitor and a β-blocker in the manufacture of a therapeutic agent for glaucoma.
Use of a combination of a Rho kinase inhibitor and a β-blocker in the manufacture of a therapeutic agent for glaucoma, characterized in that their actions are complemented and/or enhanced each other.
Dependencies are inferred from the claim text.